Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Affymetrix SNP array data for 5q- myelodysplastic syndromes

ABSTRACT: Myelodysplastic syndromes (MDS) are uncommon entities, heterogeneous clinically and cytogenetically. Recently, a new drug, Lenalidomide, has demonstrated to be very effective in patients with MDS and 5q- reaching 70% of hematological responses whereas patients with MDS without 5q- has only 20-30% of hematological responses. The aim of the present study is to determine genetic alteration in this subset of patients, and describe candidate genes related with response or resistance to Lenalidomide. The aim of the present study is to determine genetic alteration in this subset of patients, and describe candidate genes related with response or resistance to Lenalidomide. Copy number analysis of Affymetrix GenomeWide SNP 6.0 arrays was performed for 2 patients with MDS an isolated 5q- by conventional cytogenetics. There are also 2 samples from separated CD3+ lymphocytes, which were used as references for copy number and LOH inference.

ORGANISM(S): Homo sapiens

SUBMITTER: Vera Adema 

PROVIDER: E-GEOD-59244 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

The casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactivation of Csnk1a1 and found that Csnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure. Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitiz  ...[more]

Similar Datasets

Transcriptomics Affymetrix SNP array data for myelodysplastic syndrome with 5q deletion treated with lenalidomide
2013-07-01 | E-GEOD-35656 | biostudies-arrayexpress
Genomics Affymetrix SNP array data for 5q- myelodysplastic syndromes
2014-10-07 | GSE59244 | GEO
Transcriptomics Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) Myelodysplastic Syndromes and impact of lenalidomide
2024-04-18 | GSE245452 | GEO
Proteomics,Multiomics pSILAC mass spectrometry reveals ZFP91 as novel IMiD dependent substrate of the CRL4CRBN ligase - PART 1
2017-05-29 | PXD005849 | Pride
Proteomics,Multiomics pSILAC mass spectrometry reveals ZFP91 as novel IMiD dependent substrate of the CRL4CRBN ligase - PART 2
2017-05-29 | PXD005857 | Pride
Genomics Affymetrix SNP array data for myelodysplastic syndrome with 5q deletion treated with lenalidomide
2013-07-01 | GSE35656 | GEO
Transcriptomics Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
2011-04-28 | E-GEOD-28896 | biostudies-arrayexpress
Transcriptomics A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes
2016-06-08 | GSE82235 | GEO
Transcriptomics Maturation of the thalidomystery
2014-08-26 | E-GEOD-60742 | biostudies-arrayexpress
Transcriptomics Changes in gene expression profiles in patients with 5q- syndrome in CD14+ monocytes caused by lenalidomide treatment
2011-09-12 | GSE31460 | GEO